Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open Label, Randomized Study Testing the Efficacy of Retifanlimab in Combination with Bevacizumab and Hypofractionated Radiotherapy in Patients with Recurrent GBM

NCT06160206 is registered in ClinicalTrials.gov with Academic and Community Cancer Research United as lead sponsor.

NCT NCT06160206
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06160206 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open Label, Randomized Study Testing the Efficacy of Retifanlimab in Combination with Bevacizumab and Hypofractionated Radiotherapy in Patients with Recurrent GBM
Lead sponsor
Academic and Community Cancer Research United
Phase
Phase 2
Overall status
Recruiting
Start date
October 2, 2024
Completion date
November 30, 2030
Enrollment
134 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent glioblastoma, recurrent who grade 4 glioma